AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00406679
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: equivalent volume IV 0.9% sodium chloride (equivalent volume)
Trial: NCT03172598
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule
Trial: NCT03049878
Drug: Paracetamol Codeine
RxNorm normalized name: codeine and paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: preoperative administration
Trial: NCT03049878
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: preoperative administration
Trial: NCT01289886
Drug: BR-A-657
RxNorm normalized name: Respa-BR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20, 60, 120, 240, 360, 480mg or placebo tablet
Trial: NCT02570347
Drug: Co-amoxiclav
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection Co-amoxiclav 1.2 g intravenously q8h for a minimum of 48-72 hours; switched to oral Co-amoxiclav 625 mg b.i.d. when clinically appropriate.
Trial: NCT00969709
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo capsules, oral administration, once daily for 8 weeks.
Trial: NCT02956785
Drug: 10 mg Dinoprostone; CTS, UK
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02956785
Drug: 3 mg Dinoprostone vaginal tablet; Pfizer, UK
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02956785
Drug: Aquacryl hydrogel rod; HPSRx Enterprises, USA
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00922636
Drug: LY2216684
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taken in tablet form QD po.
Trial: NCT03107338
Drug: DEXKETOPROFEN TROMETAMOL
RxNorm normalized name: Dexketoprofen trometamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients who were administered a single dose of 25 mg of DKT 15 minutes before surgery
Trial: NCT00605215
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching to laquinimod will be administered per schedule specified in the arm description.
Trial: NCT00605215
Drug: Avonex®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avonex® will be administered per dose and schedule specified in the arm description.
Trial: NCT00922636
Drug: Placebo (tablet)
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo given as a tablet for LY2216684 blind QD po for the 8-week double-blind treatment phase, followed by 2 weeks in the taper phase.
Trial: NCT00922636
Drug: Placebo (capsule)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo given as a capsule for methylphenidate blind QD po for the 8-week double-blind treatment phase followed by 2 weeks in the taper phase.
Trial: NCT00023296
Drug: Nitric Oxide
RxNorm normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03127592
Drug: Fixed Dose Combination
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed Dose Combination of Etodolac 400 mg + Cyclobenzaprine 10 mg
Trial: NCT03127592
Drug: Etodolac
RxNorm normalized name: Etodolac
DrugBank: Etodolac (DB00749)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individual drug
Trial: NCT03918499
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00603304
Drug: Placebo - first 24 weeks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will take one 320 mg chocolate-colored soft gelcaps containing a placebo for 24 weeks.
Trial: NCT00603304
Drug: Placebo - weeks 48 - 72
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will take 960 (3) mg chocolate-colored soft gelcaps containing a placebo for 24 weeks.
Trial: NCT01561937
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: If the subject is eligible to continue in trial part B, trial drug will be administered i.v. as a slow bolus injection over 2 to 5 minutes in five different doses followed by two biopsies (B2) and (B3) 15 minutes and 5 hours and 15 minutes, respectively, after trial drug administration
Trial: NCT01019161
Drug: AZD1152
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100mg Lyophile, 5mL Diluent IV infusion
Trial: NCT01019161
Drug: C14 AZD1152
RxNorm normalized name: C14-22 alcohols
FDA approved: no
EMA approved: no
PMDA approved: no
Description: radiolabelled IV solution, 1.05 mg/ml presented as 15 ml fill in 20ml vial infusion
Trial: NCT00266227
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous repeating dose
Trial: NCT00266227
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral or parenteral repeating dose
Trial: NCT00649480
Drug: COLAZAL® Capsules 750 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3x750mg, single dose fed
Trial: NCT02874066
Drug: PTV/r/OBV/DSV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Viekirax/Exviera for 12 weeks
Trial: NCT03374345
Drug: Sipjeondaebo-tang Granule
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3g, three times a day, each taken before or between meals Manufacturing company: HANPOONG PHARM \& FOODS Co. Ltd.
Trial: NCT03374345
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3g, three times a day, each taken before or between meals Manufacturing company: HANPOONG PHARM \& FOODS Co. Ltd.
Trial: NCT01850446
Drug: Ergoferon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Safety and Efficacy
Trial: NCT01056692
Drug: OC000459
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules twice daily for 15 days
Trial: NCT01056692
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules twice daily for 15 days
Trial: NCT03837210
Drug: Pylorin
RxNorm normalized name: Helicobacter pylori
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Poly Herbal formulation
Trial: NCT01595373
Drug: Acyl ghrelin
RxNorm normalized name: gellan gum (low acyl)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acyl ghrelin 12.5 pg/min infused continuously for 300 minutes
Trial: NCT01595373
Drug: Placebo (Ringer acetate)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ringer acetate 2 microliter/min for 300 minutes
Trial: NCT01127100
Drug: transdermal fentanyl matrix, gabapentin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: transdermal fentanyl matrix: during 1st to 6th days, 12ug/h of fentanyl matrix will be applied. During 7th to 28th days, the dosage of fentanyl matrix will be increased until the pain score decrease not more than 2 every 6 days. The maximal dosage is 100ug/h. During 29th to 56th days, the dosage will be maintained.~Gabapentin: the 1st day, 300mg hs, the 2nd day, 300mg bid, the 3th to 4th days, 300mg tid, the 5th to 6th days, 300mg-300mg-600mg the 7th to 28 days, the dosage will be increased until the pain score decreased not more than 2 and the maximal dose is 2400mg per day. During 29th to 56th days, the dosage will be maintained.
Trial: NCT02308501
Drug: Lastacaft ®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02308501
Drug: Tears Naturale ® (Placebo)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04072042
Drug: Apatinib monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients will receive Apatinib 250mg tablet by mouth, bid.
Trial: NCT02074202
Drug: 18F- fluorocholine
RxNorm normalized name: (18F)-Fluoride
DrugBank: Fluoride ion F-18 (DB09398)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To compare the diagnostic efficacy of FCH PET scan to FDG PET scan.
Trial: NCT02074202
Drug: 18F- fluorodeoxyglucose
RxNorm normalized name: fluorodeoxyglucose F18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To compare the diagnostic efficacy of FCH PET scan to FDG PET scan
Trial: NCT01455870
Drug: ITCA 650 60 mcg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: exenatide in DUROS
Trial: NCT02169440
Drug: BIA 9-1067
RxNorm normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIA 9-1067 25 mg
Trial: NCT03927573
Drug: GEM3PSCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of GEM3PSCA, administered intravenously, continuously over 7 days, 2 cycles
Trial: NCT01164644
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will take twelve pills by mouth three times a day over four days.
Trial: NCT00619827
Drug: 300 IR grass pollen allergen extract tablet
RxNorm normalized name: orchard grass pollen extract 300 IR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 IR grass pollen allergen extract tablet once daily during four months
Trial: NCT00619827
Drug: Placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet once daily during four months
Trial: NCT00524927
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00621777
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At each weekly study visit from the baseline visit to study week 11,ALL subjects will receive a one-week supply of varenicline with instructions on how to take the study medication. Titration is as follows: 0.5 mg varenicline per day for 3 days, then 0.5 mg twice per day for 4 days, and then 1 mg twice per day for 11 weeks.~In addition, participants who enter the relapse prevention phase and are randomized to the placebo condition will receive placebo pills for 40 weeks.
Trial: NCT03485443
Drug: %0.9 NaCl 10ml/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluid administration
Trial: NCT03485443
Drug: %0.9 NaCl 20ml/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluid administration
Trial: NCT00194129
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pills that looked exact to divaloproex were provided to subjects and take twice daily.
Trial: NCT00112827
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01165307
Drug: Estradiol 30mcg / Levonorgestrel 150mcg monophasic oral contraceptive pills
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each packet consists of a fixed dose of 30mcg estradiol and a 150mcg dose of levonorgestrel for the first 21 days of the cycle, followed by a 7 day pill free period. Subjects will be instructed to administer the pills orally, starting 5 days after the start of menstrual blood flow, continuing cyclically, thus allowing for withdrawal bleeding after the 21 day pill cycle.
Trial: NCT00353522
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: po daily for 24 weeks
Trial: NCT01165307
Drug: Naproxen sodium pills
RxNorm normalized name: naproxen sodium Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As an alternative to oral contraceptive pills, subjects may take Naproxen 500 mg with onset of menses, then 250 mg three times daily for the duration of the menses (or maximum of five days)
Trial: NCT03234036
Drug: GSK2838232 100 mg tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: It is a white to slightly colored tablet. It will be supplied as prefilled tablets in bulk for dispensing to subjects at the site according to the treatment code.
Trial: NCT03234036
Drug: GSK2838232 50 mg capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: It is a pink unmarked capsule. It will be supplied as prefilled capsules in bulk for dispensing to subjects at the site according to the treatment code.
Trial: NCT03234036
Drug: Placebo for GSK2838232 tablets
RxNorm normalized name: PLACEBO TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: It is a white to slightly colored tablet. The placebo tablets supplied will not be identical to GSK2838232 tablets. It will be administered by site staff via an opaque card or paper tube.
Trial: NCT01126099
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules twice daily for 12 weeks
Trial: NCT05014711
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Before infusion, remifentanil is given 0.3 g/kg slowly intravenous injection more than 60 seconds, and the initial dose is 0.025ug/kg/min. The dosage is adjusted to achieve the target depth of analgesia and sedation (CPOT \< 3, RASS -2 to 1), with each change 0.025ug/kg/min and the maximum dose 0.15ug/kg/min.
Trial: NCT05014711
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Before infusion, fentanyl is given 0.3 g/kg slowly intravenous injection more than 60 seconds, and the initial dose is 0.025ug/kg/min. The dosage is adjusted to achieve the target depth of analgesia and sedation (CPOT \< 3, RASS -2 to 1), with each change 0.025ug/kg/min and the maximum dose 0.15ug/kg/min.
Trial: NCT02984293
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once daily for 28 days.
Trial: NCT01879722
Drug: TAK-063 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-063 placebo-matching tablets
Trial: NCT02468180
Drug: Lauromacrogol
RxNorm normalized name: Lauromacrogol
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02580305
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily, tablets, orally
Trial: NCT02828540
Drug: HT047 High-dose group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HT047 2250mg, three times a day dosing schedule, 3 tablets per dose
Trial: NCT00481624
Drug: Epoetin Alfa plus Iron
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1. One (1) injection of Procrit®, by needle, inserted just under the skin;~2. 125 mg of ferric gluconate (an iron injection product), through an IV injection into a vein.~These injections will take approximately 10-15 minutes to complete. Both will be administered every 3 weeks for a total of 4 cycles, unless the study doctor decides that a change in the amount of Procrit® and iron is necessary once the hemoglobin level rises or is above a certain amount.~In addition to Procrit® and the intravenous iron, the subject will also receive platinum-containing chemotherapy every 3 weeks for 4 cycles as per standard of care for their lung cancer treatment. Radiation therapy will be allowed during this regimen if it is part of the subject's treatment plan.
Trial: NCT00003601
Drug: tretinoin
RxNorm normalized name: Tretinoin
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01237275
Drug: SSRI treated group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: characterize in arm of a study (SSRI treated group)
Trial: NCT02453464
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Leucovorin: IV solution, IV over 2 hours, 400 mg/m², Every 14 days, Until disease progression/toxicity
Trial: NCT01469793
Drug: DMOT4039A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DMOT4093A will be administered by intravenous infusion on either a Q3W or a Q1W dosing schedule, in 21-day cycles.
Trial: NCT01216982
Drug: Lovaza, omega-3 fatty acid ethyl ester
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three 1g capsules/day for three months; this corresponds to a total of 2520mg EPA+DHA/day
Trial: NCT01812434
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg three times daily for 28 days
Trial: NCT00774930
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: deep s.c. injection of placebo (0.9% saline solution) every 4 weeks (±3 days) for 16 weeks, then deep s.c. injection of lanreotide 120 mg, every 4 weeks (±3 days).
Trial: NCT01216982
Drug: Placebo, visually identical to Lovaza
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three 1g corn oil capsules/day for three months
Trial: NCT01236534
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo twice daily for 21 days.
Trial: NCT01079663
Drug: Placebo chip
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00085059
Drug: boronophenylalanine-fructose complex
RxNorm normalized name: Fructose
DrugBank: Fructose (DB04173)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01100853
Drug: VIVITROL injection and VIVITROL Placebo Injection , 24 weeks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efficacy of 24 week course of VIVITROL with counseling as compared to 24 week course of VIVITROL placebo with counseling (monthly injections)
Trial: NCT02528526
Drug: OXY111A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OXY111A intravenous infusion
Trial: NCT02546648
Drug: Rosuvastatin or matching placebo
RxNorm normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects who are not on a statin will also be randomized to Rosuvastatin or Rosuvastatin placebo. 40mg preoperatively, followed by 20mg postoperatively (4-6 hours after surgical close) and 20mg/day for 30 days postoperatively.
Trial: NCT01034163
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01725685
Drug: FF/UMEC 400/500 mcg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FF/UMEC will be available as 100/125 mcg strength administered as 4 inhalations from a DPI
Trial: NCT02355678
Drug: Local anesthetic infiltration
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Using 25 G-3.5 cm curved needle
Trial: NCT02355678
Drug: General anesthesia
RxNorm normalized name: Ethers for general anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction by intravenous fentanyl (1.5 µg kg-1) and propofol (2.5 mg kg-1) followed by endotracheal intubation facilitated by atracurium (0.5 mg kg-1).~Maintenance with sevoflurane 1-3%, fentanyl (1-2 µg kg-1), nitrous oxide 70% and oxygen 30%.
Trial: NCT02355678
Drug: Paracetamol Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: If Visual Analogue Scale was less than 4
Trial: NCT02832401
Drug: Caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02832401
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00752557
Drug: rhBMP-2/CPM injection and bisphosphonates, calcium, and vitamin D (oral bisphosphonate therapy)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single, unilateral intraosseous injection of 6mL of rhBMP-2/CPM , 1.0 mg/mL.
Trial: NCT00752557
Drug: rhBMP-2/CPM injection and bisphosphonates, calcium, and vitamin D (oral bisphosphonate therapy)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single, unilateral intraosseous injection of 6mL of rhBMP-2/CPM , 2.0 mg/mL.
Trial: NCT00702780
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5mg/day for 2 weeks, 10mg/day for 2 weeks and 20mg/day for 48 weeks (maintaining donepezil at the previous stable dose during the whole trial period)
Trial: NCT01486940
Drug: insulin NPH
RxNorm normalized name: insulin NPH human isophane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individually adjusted dose administered subcutaneously (s.c., under the skin) twice daily
Trial: NCT01486940
Drug: human soluble insulin
RxNorm normalized name: Recombinant human soluble insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individually adjusted dose administered subcutaneously (s.c., under the skin) prior to meals
Trial: NCT01128452
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPMC Placebo capsules, once daily for 28 days
Trial: NCT03107429
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo was a sugar based placebo placed in a capsule.
Trial: NCT00122434
Drug: BEA 2180 BR
RxNorm normalized name: Respa-BR
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02960412
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline given intraoperatively as placebo
Trial: NCT02932436
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: amount of Placebo corresponding to empagliflozin 10 mg per os daily for 12 weeks
Trial: NCT03150082
Drug: GR37547 tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single tablet of GR37547 should be taken orally with 240 mL of water. GR37547 500 mg tablet will be a white to off white capsule shape with break line on upper side and embossed GSK500on lower side.
Trial: NCT02487446
Drug: QVA149
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QVA149 capsules for inhalation, delivered via QVA149 single dose dry powder inhaler (SDDPI)
Trial: NCT02487446
Drug: Placebo (QVA149)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo to QVA149 capsules for inhalation, delivered via QVA149 SDDPI
Trial: NCT02810587
Drug: Topical antibiotics following injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Either receive or not receive topical antibiotics following intravitreous injection
Trial: NCT00726544
Drug: ARC1779 Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARC1779 Injection or placebo is administered intravenously to patients as an initial loading dose followed by continuous infusion of up to 14 days plus 2 day taper. Treatment with ARC1779 Injection is to be given at low dosage that is intended to produce target steady-state ARC1779 plasma concentrations during infusion of 3μg/mL.
Trial: NCT00726544
Drug: ARC1779 Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARC1779 Injection or placebo is administered intravenously to patients as an initial loading dose followed by continuous infusion of up to 14 days plus 2 day taper. Treatment with ARC1779 Injection is to be given at low dosage that is intended to produce target steady-state ARC1779 plasma concentrations during infusion of 12μg/mL.